ANIP Ani Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP

Price (delayed)

$50.54

Market cap

$1.03B

P/E Ratio

95.36

Dividend/share

N/A

EPS

$0.53

Enterprise value

$1.13B

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
Ani Pharmaceuticals's net income has surged by 120% YoY
The company's EPS has surged by 111% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com/
Peers: JAZZ TEVA PFE CAH

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
20.44M
Market cap
$1.03B
Enterprise value
$1.13B
Valuations
Price to earnings (P/E)
95.36
Price to book (P/B)
2.39
Price to sales (P/S)
2.15
EV/EBIT
26.87
EV/EBITDA
10.93
EV/Sales
2.5
Earnings
Revenue
$449.39M
EBIT
$41.9M
EBITDA
$102.95M
Free cash flow
$60.09M
Per share
EPS
$0.53
Free cash flow per share
$3.14
Book value per share
$21.18
Revenue per share
$23.5
TBVPS
$33.56
Balance sheet
Total assets
$889.91M
Total liabilities
$435.2M
Debt
$285.88M
Equity
$429.86M
Working capital
$362.87M
Liquidity
Debt to equity
0.67
Current ratio
3.7
Quick ratio
2.77
Net debt/EBITDA
0.9
Margins
EBITDA margin
22.9%
Gross margin
63.4%
Net margin
3%
Operating margin
9.6%
Efficiency
Return on assets
1.4%
Return on equity
3.2%
Return on invested capital
7%
Return on capital employed
5.5%
Return on sales
9.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
1.47%
1 week
-2.53%
1 month
-18.03%
1 year
30.09%
YTD
25.63%
QTD
-12.95%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$449.39M
Gross profit
$284.98M
Operating income
$42.96M
Net income
$13.38M
Gross margin
63.4%
Net margin
3%
The company's operating income has surged by 171% YoY and by 71% QoQ
ANIP's operating margin has surged by 145% year-on-year and by 52% since the previous quarter
Ani Pharmaceuticals's net income has surged by 120% YoY
The net margin has soared by 113% YoY

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
ANIP P/E details
P/E
95.36
P/B
2.39
P/S
2.15
EV/EBIT
26.87
EV/EBITDA
10.93
EV/Sales
2.5
The company's EPS has surged by 111% YoY
The company's equity rose by 38% YoY and by 4.9% QoQ
The P/B is 6% below the 5-year quarterly average of 2.5 and 2.1% below the last 4 quarters average of 2.4
Ani Pharmaceuticals's revenue has soared by 59% YoY and by 12% from the previous quarter
The price to sales (P/S) is 15% lower than the 5-year quarterly average of 2.5 and 3.6% lower than the last 4 quarters average of 2.2

Efficiency

How efficient is Ani Pharmaceuticals business performance
Ani Pharmaceuticals's ROIC has soared by 164% YoY and by 119% from the previous quarter
The company's return on sales has surged by 142% YoY and by 98% QoQ
The ROA has soared by 115% YoY
The return on equity has surged by 115% year-on-year

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 104% more than its total liabilities
Ani Pharmaceuticals's total assets has increased by 20% YoY and by 3.6% from the previous quarter
ANIP's quick ratio is up by 12% year-on-year
The debt is 33% lower than the equity
The company's equity rose by 38% YoY and by 4.9% QoQ
The debt to equity has decreased by 27% YoY and by 4.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.